Insider Selling: Maze Therapeutics (NASDAQ:MAZE) CEO Sells $181,532.00 in Stock

Posted by Francis Steltz on May 30th, 2026

Maze Therapeutics, Inc. (NASDAQ:MAZE – Get Free Report) CEO Jason Coloma sold 6,982 shares of Maze Therapeutics stock in a transaction on Friday, May 22nd. The stock was sold at an average price of $26.00, for a total transaction of $181,532.00. Following the sale, the chief executive officer directly owned 28,523 shares of the company’s stock, valued at $741,598. This represents a 19.66% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Maze Therapeutics Price Performance

MAZE opened at $26.46 on Friday. Maze Therapeutics, Inc. has a 52 week low of $9.73 and a 52 week high of $53.65. The firm has a market capitalization of $1.46 billion, a PE ratio of -10.46 and a beta of 2.50. The company has a debt-to-equity ratio of 0.11, a quick ratio of 17.88 and a current ratio of 17.88. The company has a fifty day moving average price of $28.77 and a two-hundred day moving average price of $37.52.

Maze Therapeutics (NASDAQ:MAZE – Get Free Report) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.02). The firm had revenue of $20.00 million for the quarter. As a group, analysts anticipate that Maze Therapeutics, Inc. will post -2.74 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Royal Bank of Canada grew its position in shares of Maze Therapeutics by 128.3% during the 4th quarter. Royal Bank of Canada now owns 646 shares of the company’s stock worth $27,000 after purchasing an additional 363 shares in the last quarter. GF Fund Management CO. LTD. acquired a new position in shares of Maze Therapeutics during the 4th quarter worth approximately $39,000. Ameritas Investment Partners Inc. grew its position in shares of Maze Therapeutics by 82.6% during the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock worth $42,000 after purchasing an additional 738 shares in the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in shares of Maze Therapeutics during the 4th quarter worth approximately $43,000. Finally, Russell Investments Group Ltd. grew its position in shares of Maze Therapeutics by 947.8% during the 3rd quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock worth $49,000 after purchasing an additional 1,725 shares in the last quarter.

Wall Street Analyst Weigh In

MAZE has been the topic of several analyst reports. BTIG Research reissued a “buy” rating and set a $46.00 price target on shares of Maze Therapeutics in a research report on Wednesday, March 25th. JPMorgan Chase & Co. boosted their price target on shares of Maze Therapeutics from $52.00 to $58.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 31st. HC Wainwright upped their target price on shares of Maze Therapeutics from $60.00 to $110.00 and gave the company a “buy” rating in a report on Wednesday, March 25th. Wedbush upped their target price on shares of Maze Therapeutics from $43.00 to $58.00 and gave the company an “outperform” rating in a report on Monday, March 16th. Finally, Guggenheim upped their target price on shares of Maze Therapeutics from $46.00 to $58.00 and gave the company a “buy” rating in a report on Wednesday, March 4th. Two research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Maze Therapeutics presently has an average rating of “Buy” and an average target price of $66.00.

Get Our Latest Report on Maze Therapeutics

About Maze Therapeutics

(Get Free Report)

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.